

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Dihydroergotamine Mesylate Injection, USP

This recall has been initiated on **the retail level** due to the product's yellow coloration and its failure to meet established specifications, which may negatively impact the product's efficacy and raise potential safety concerns. This recall should be carried out at the level of hospitals and pharmacy retail. Shipping began on **30th May 2024**.

Name	NOC	Exp date	Batch number
Dihydroergotamine Mesylate Injection, USP, 1 mg/ml Ampules,	81284-411-05	12/2025	F9026F01 F9026F02